Merck & Co., Inc. (MRK)
Merck is a global healthcare giant that discovers and manufactures life-saving medicines and vaccines to treat everything from cancer to infectious diseases.
Is Merck & Co., Inc. a good stock for a UK beginner?
The honest version: Merck is a global healthcare giant that discovers and manufactures life-saving medicines and vaccines to treat everything from cancer to infectious diseases.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Breakthrough innovation in oncology or vaccine technology.
Failure to replace expiring patents with new, profitable drugs.
What does Merck & Co., Inc. do?
Merck makes its money by researching, developing, and selling prescription drugs and vaccines to hospitals and pharmacies worldwide. Their business model relies heavily on their ability to keep inventing new treatments to replace older ones as patents expire. Keep an eye on their 'pipeline'—the collection of new drugs currently in clinical trials—because it shapes their future growth.
On our factor screen it looks strongest on momentum and quality, and weakest on growth.
- ✓Pays a dividend - about 2.6% a year
- ✓Growing - revenue up about 5% over the year
- !High P/E of 36 - big growth is already priced in
- ✓Strong return on shareholder money (ROE 19%)
- Momentum screens high (84/100)
- High profit margins on successful drugs
- Strong track record of scientific innovation
- Low volatility compared to the broader market
- Growth screens low (29/100)
- Patent cliffs where exclusivity ends and sales drop
- Changes in government healthcare pricing policies
- Clinical trial failures that waste years of investment
What do Merck & Co., Inc.'s numbers mean?
How much money does Merck & Co., Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Merck & Co., Inc. pay a dividend?
Yes - Merck & Co., Inc. currently pays a dividend of about 2.6% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does Merck & Co., Inc. report earnings, and how did recent quarters go?
Merck & Co., Inc. is next scheduled to report on about 2026-08-04 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-04-30 | $-1.47 | $-1.28 | Beat +13% |
| 2026-02-03 | $2.01 | $2.04 | Beat +1% |
| 2025-10-30 | $2.35 | $2.58 | Beat +10% |
| 2025-07-29 | $2.03 | $2.13 | Beat +5% |
| 2025-04-24 | $2.14 | $2.22 | Beat +4% |
| 2025-02-04 | $1.67 | $1.72 | Beat +3% |
Across the last 6 quarters here, Merck & Co., Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Merck & Co., Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Merck & Co., Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High profit margins on successful drugs
- Strong track record of scientific innovation
- Low volatility compared to the broader market
- Consistent dividend payments to shareholders
- Heavy reliance on a few 'blockbuster' drugs
- High costs associated with research and development
- Complex regulatory environment
- Pressure from generic drug manufacturers
- Patent cliffs where exclusivity ends and sales drop
- Changes in government healthcare pricing policies
- Clinical trial failures that waste years of investment
- Legal challenges regarding product safety
The write-up's own warning lights — if these start happening, the case above changes.
- A major, permanent change in how governments regulate drug pricing
- A complete failure of the company's research pipeline to produce new medicines
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.